[PET/CT for Diagnostics and Therapy Stratification of Lung Cancer]

Overview

Journal Radiologe

Specialty Radiology

Date 2010 Jul 24

PMID 20652216

Citations 8

Authors

C Kratochwil

U Haberkorn

F L Giesel

Affiliations

Soon will be listed here.

Abstract

With the introduction of positron emission tomography (PET) and more recently the hybrid systems PET/CT, the management of cancer patients in the treatment strategy has changed tremendously. The combination of PET with multidetector CT scanning enables the integration of metabolic and high resolution morphological image information. PET/CT is nowadays an established modality for tumor detection, characterization, staging and response monitoring. The increased installation of PET/CT systems worldwide and also the increased scientific publications underline the importance of this imaging modality. PET/CT is particular the imaging modality of choice in lung cancer staging and re-staging (T, N and M staging). The possible increased success of surgery in lung cancer patients and also the expected reduction in additional invasive diagnostics lead to benefits for both the individual patient and the healthcare system. In this review article PET and PET/CT is presented for diagnostic and therapeutic stratification in lung cancer. The fundamentals of glucose metabolism, staging, tumor recurrence and therapeutic monitoring are presented.

Citing Articles

Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Flechsig P, Hural O, Kreuter M, Eichhorn M, Heussel G, Sachpekidis C In Vivo. 2018; 32(6):1457-1462.

PMID: 30348701 PMC: 6365762. DOI: 10.21873/invivo.11399.

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Flechsig P, Rastgoo R, Kratochwil C, Martin O, Holland-Letz T, Harms A Mol Imaging Biol. 2018; 20(6):1044-1052.

PMID: 29679299 DOI: 10.1007/s11307-018-1196-9.

Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Flechsig P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J Mol Imaging Biol. 2016; 19(2):315-322.

PMID: 27539308 DOI: 10.1007/s11307-016-0996-z.

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Flechsig P, Choyke P, Kratochwil C, Warth A, Antoch G, Holland Letz T Diagn Interv Radiol. 2015; 22(1):35-9.

PMID: 26611258 PMC: 4712895. DOI: 10.5152/dir.2015.15220.

A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Flechsig P, Kratochwil C, Warth A, Rath D, Eichwald V, Huber P Mol Imaging Biol. 2015; 18(2):243-8.

PMID: 26330160 DOI: 10.1007/s11307-015-0890-0.

References

Gorenberg M, Bar-Shalom R, Israel O . Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol. 2008; 81(970):821-5. DOI: 10.1259/bjr/26210052. View

Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A . PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004; 45(10):1640-6. View

Krupitskaya Y, Eslamy H, Nguyen D, Kumar A, Wakelee H . Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol. 2009; 4(3):429-31. DOI: 10.1097/JTO.0b013e3181989e12. View

Naalsund A, Maublant J . The solitary pulmonary nodule--is it malignant or benign? Diagnostic performance of Tc-depreotide SPECT. Respiration. 2006; 73(5):634-41. DOI: 10.1159/000093232. View

Rajendran J, Schwartz D, OSullivan J, Peterson L, Ng P, Scharnhorst J . Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006; 12(18):5435-41. PMC: 4737549. DOI: 10.1158/1078-0432.CCR-05-1773. View

Hicks R . Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009; 50 Suppl 1:31S-42S. DOI: 10.2967/jnumed.108.057216. View

Pauls S, Buck A, Hohl K, HALTER G, Hetzel M, Blumstein N . Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin. 2007; 46(1):9-14. View

Kuehl H, Veit P, Rosenbaum S, Bockisch A, Antoch G . Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J Nucl Med. 2007; 48 Suppl 1:45S-57S. View

Halley A, Hugentobler A, Icard P, Porret E, Sobrio F, Lerochais J . Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2005; 32(9):1026-32. DOI: 10.1007/s00259-005-1812-1. View

10.

Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke H . Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2006; 33(7):823-30. DOI: 10.1007/s00259-005-0063-5. View

11.

Kruger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C . Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36(11):1807-12. DOI: 10.1007/s00259-009-1181-2. View

12.

Buck A, Herrmann K, Stargardt T, Dechow T, Krause B, Schreyogg J . Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med. 2010; 51(3):401-12. DOI: 10.2967/jnumed.108.059584. View

13.

Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D . Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008; 61(1):35-43. DOI: 10.1016/j.lungcan.2007.11.007. View

14.

Menda Y, Kahn D . Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med. 2002; 32(2):92-6. DOI: 10.1053/snuc.2002.31564. View

15.

Juweid M, Cheson B . Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507. DOI: 10.1056/NEJMra050276. View

16.

Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y . Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol. 2009; 11(6):467-72. DOI: 10.1007/s11307-009-0227-y. View

17.

Lee D, Kim S, Lee H, Lee S, Park S, Kim H . Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):816-21. DOI: 10.1097/JTO.0b013e3181a99fde. View

18.

Everitt S, Hicks R, Ball D, Kron T, Schneider-Kolsky M, Walter T . Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 75(4):1098-104. DOI: 10.1016/j.ijrobp.2008.12.039. View

19.

Abramyuk A, Tokalov S, Zophel K, Koch A, Lazanyi K, Gillham C . Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol. 2009; 91(3):399-404. DOI: 10.1016/j.radonc.2009.01.003. View

20.

Freudenberg L, Rosenbaum S, Beyer T, Bockisch A, Antoch G . PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am. 2007; 45(4):639-44, v. DOI: 10.1016/j.rcl.2007.05.003. View